GlassScriptPhysician profile
Gregory Norcross
NPI 1881190338
$4,972.36
in general payments reported to CMS, 2019-2025
10 companies · $3,669 in 2025
The $3,669 reported for 2025 was more than what 78% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.95 · 2023: $16.12 · 2024: $1,272 · 2025: $3,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,741 · Food and Beverage: $2,054 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,740.98 |
| Food and Beverage | $2,053.94 |
| Education | $162.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,864.57 | 2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $1,570.55 | 2025 | Optis, Mitraclip |
| Medtronic, INC. | $1,152.53 | 2024 | Corevalve Evolut R, Onyx Frontier |
| Abiomed | $157.92 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $88.33 | 2024 | |
| Pfizer INC. | $47.19 | 2021-2024 | |
| Philips North America LLC | $35.85 | 2025 | Ineb Devices |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.54 | 2025 | Lifevest |
| Chiesi USA, INC. | $17.66 | 2025 | Kengreal |
| Amgen INC. | $15.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Norcross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.